Why is bcrx down

BioCryst Pharmaceuticals (BCRX) has experienced a decrease in its stock price due to several factors:

1. Discontinuation of Drug Development: BioCryst's decision to discontinue the development of BCX9930, a drug being evaluated for paroxysmal nocturnal hemoglobinuria (PNH) and other disorders, has negatively impacted the company's stock price. The company cited new competitive data and the limitations of optimizing the dosing of BCX9930 as reasons for the discontinuation. This decision suggests that the company may face challenges in developing effective treatments, which can erode investor confidence.
2. Clinical Trial Setbacks: The company faced a partial clinical hold on the BCX9930 program due to observed elevations in serum creatinine in some patients, indicating drug-related kidney injury. Although the FDA subsequently lifted the partial clinical hold, the temporary halt in enrollment may have raised concerns about the safety and efficacy of the drug.

In conclusion, the decline in BCRX's stock price can be attributed to the company's decision to discontinue the development of its drug candidate, BCX9930, and the associated clinical trial setbacks. These factors have likely led to concerns among investors about the company's prospects and the potential for future revenue and earnings.